Coreline Soft, a medical artificial intelligence (AI) company, has joined a clinical research project on early lung cancer detection in Switzerland as an AI partner. The study is being conducted by Kantonsspital Aarau (KSA), a major teaching and research hospital in Switzerland, in collaboration with AstraZeneca Switzerland AG.
The joint research aims to go beyond evaluating algorithm accuracy and instead focus on verifying how AI can function within real clinical environments. The study will assess how AI technologies can support healthcare professionals in day-to-day clinical workflows rather than simply demonstrating technical performance.
The global medical AI market is gradually shifting from a phase dominated by accuracy-focused algorithm competition toward operational AI that can continuously function within clinical workflows. In large medical institutions, where patient volumes are high and multidisciplinary team (MDT) discussions are routine, the key evaluation criterion is no longer whether AI can replace physicians’ interpretation, but how effectively it can improve efficiency and consistency in clinical decision-making.
Against this backdrop, the collaboration between a hospital, a pharmaceutical company, and an AI developer is seen as a case study in integrating AI not as a standalone solution but as part of the broader clinical infrastructure.
Rather than focusing on short-term commercial outcomes, the research will observe over an extended period how AI can contribute to MDT discussions by providing reference insights and how it may reduce the workload associated with repetitive image analysis and patient management tasks. The initiative is expected to generate real-world clinical evidence supporting long-term adoption and market entry of AI technologies in healthcare.
Industry observers say this type of collaboration could become a typical model for the future expansion of medical AI. As regulatory, clinical, and operational requirements grow more complex, only AI technologies validated within real healthcare systems are likely to expand into national screening programs, multi-institutional networks, and global clinical studies.
Through this collaboration, Coreline Soft aims to accumulate real-world clinical experience and strengthen its position in the global medical AI market as a provider of “clinically validated AI.”
The research is expected to run for one to three years and will evaluate whether AI can meaningfully contribute to multidisciplinary decision-making and improve diagnostic efficiency in high-volume clinical environments.
Meanwhile, Coreline Soft recently demonstrated its screening operations integration platform, AVIEW HUB, at the European Congress of Radiology (ECR) held in Vienna, Austria, from March 3 to 8, where it also shared national-level screening case studies from several European countries.
